KINNATE BIOPHARMA INC (KNTE)

US49705R1059 - Common Stock

1.47  +0.09 (+6.52%)

KINNATE BIOPHARMA INC

NASDAQ:KNTE (9/27/2023, 7:00:02 PM)

1.47

+0.09 (+6.52%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-08 2023-11-08/amc
Ins Owners0.35%
Inst Owners85.67%
Market Cap69.23M
Shares47.09M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts85.71
IPO12-03 2020-12-03
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KNTE Daily chart

Company Profile

Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).

Company Info

KINNATE BIOPHARMA INC

11975 El Camino Real, Ste 101, Suite 101

San Diego CALIFORNIA 92130

P: 18582994699.0

CEO: Nima Farzan

Employees: 84

Website: https://www.kinnate.com/

KNTE News

News Image9 days ago - ChartmillThese stocks are gapping in today's session

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

News Image9 days ago - ChartmillWondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

News Image9 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!

News Image9 days ago - Seeking AlphaKinnate slashes workforce by 70%, shelves three drug programs (KNTE)

Kinnate Biopharma (KNTE) said late Monday that it was slashing its workforce by 70% as part of a reprioritization of its drug development programs. Read more here.

News Image9 days ago - Kinnate BiopharmaKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
News Image9 days ago - Kinnate BiopharmaKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring

Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to...

KNTE Twits

Here you can normally see the latest stock twits on KNTE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example